In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sunrise Medical

This article was originally published in The Gray Sheet

Executive Summary

Gaining liquid oxygen products and a "demand oxygen delivery" device through the acquisition of Pierce, Florida-based Pulsair, Inc. The demand oxygen delivery device "reduces waste and cost by limiting delivery of oxygen to the inhalation segment of the breathing cycle," Sunrise claims. Pulsair, which had 1993 sales of about $7 mil., will operate as a unit of Sunrise's DeVilbiss respiratory products division, which makes nebulizers, concentrators and sleep apnea products. Pulsair products will enable DeVilbiss "to address the home respiratory market with the full-range of oxygen therapy modalities for patients with chronic obstructive lung disease," Sunrise Chairman and CEO Richard Chandler stated in a Jan. 24 press release. Pulsair manufacturing operations will remain at the Florida facility



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts